Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.
Hum Psychopharmacol
; 30(2): 70-84, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25676060
ABSTRACT
OBJECTIVE:
The purpose of this literature database search-based review was to critically consider and evaluate the findings of literature focusing on efficacy and safety of 5-HT3 antagonists in the treatment of obsessive-compulsive disorder (OCD), so as to test whether preclinical data match clinical therapeutic trials.DESIGN:
The PubMed database has been searched for papers on 5-HT3 antagonists and OCD in humans and for animal models of OCD and 5-HT3 receptors.RESULTS:
Of the clinically tested 5-HT3 receptor antagonists, ondansetron has been used to treat OCD in five therapeutic studies, whereas granisetron only in one recent trial. Both showed some efficacy in open studies and superiority to placebo in double-blind studies, along with fair safety. No animal OCD model directly implicated 5-HT3 receptors.CONCLUSIONS:
Overall, results indicate some utility, but the available literature is too scanty to allow for valid conclusions to be drawn. The mismatch between animal models of obsessive-compulsive disorder and clinical data with 5-HT3 antagonists needs more clinical data to ensure that it is not an artefact.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antagonistas do Receptor 5-HT3 de Serotonina
/
Transtorno Obsessivo-Compulsivo
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
/
Systematic_reviews
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article